Hepatitis B virus-specific T cell responses
AssigneeOregon Health & Science University
InventorsKlaus J. Früh, Louis J. Picker, Benjamin J. Burwitz, Scott G. Hansen, Jonah B. Sacha
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods to generate an immune response for the treatment or prevention of hepatitis B virus infection. This disclosure also relates to methods to generate MHC-E and/or MHC-II restricted CD8+ T cells for the treatment or prevention of hepatitis B virus infection.
Claims6
A method of generating an immune response to a hepatitis B virus (HBV) in a subject, the method comprising administering to the subject a cytomegalovirus (CMV) vector expressing a HBV antigen in an amount effective to elicit a CD8+ T cell response to the HBV antigen, wherein the CMV vector does not express UL128, UL130, UL146, and UL147 proteins or orthologs thereof, wherein the hepatitis B antigen is PSVRDLLDTASALYR (SEQ ID NO:
- 17) or TALRQAILCWGELMT (SEQ ID NO:
- 18).
Dependencies are inferred from the claim text.